144 chapter 2 Table 20. Baseline characteristics of included studies investigating BRAF/RAS mutations reference country study design ntot ni included indeterminate cytology Cantara 2010 Italy PS 235 41 indeterminate Moses 2010 USA PS 455 110 follicular or Hürthle cell neoplasm Nikiforov 2011 USA PS 1,056 461 Bethesda III or IV Mancini 2012 Italy n.s. 260 48 Thy3 Ohori 2013 USA RS 483 424 Bethesda IV, excluding SHCN/HCN Beaudenon-Huibregtse 2014 USA PS 806 80 Bethesda III or IV Danilovic 2014 Brazil PS 202 136 Bethesda III or IV Eszlinger 2014 (1) Denmark RS 310 164 indeterminate Eszlinger 2014 (2) Germany PS 154 125 follicular neoplasm or microfollicular proliferation Liu 2014 China PS 314 52 Bethesda III or IV Nikiforov 2014 USA PS+RS 143 143 Bethesda IV Eszlinger 2015 Italy RS 347 163 Thy3 Gill 2015 Canada RS 60 60 Bethesda III or IV Giovanella 2015 Switzerland PS 61 61 Bethesda IV Hwang 2015 South Korea PS 564 564 Bethesda III Le Mercier 2015 Belgium RS 34 34 indeterminate Nikiforov 2015 USA PS 465 462 Bethesda III Rossi 2015 Italy PS 940 118 Bethesda III or IV Valderrabano 2016 USA RS 116 105 Bethesda III or IV TOTAL 7,005 3,351 ntot: total number of thyroid nodules in study. ni: total number of indeterminate thyroid nodules included in our analysis. PS: prospective. RS: retrospective. TN: thyroid nodule. n.s.: not specified. n.o.s.: not otherwise specified. f/u: follow-up. PCR: polymerase chain reaction. FMCA: fluorescence melting curve analysis. HRM: High resolution melting. SHCN/HCN: cytology (suspicious for a) Hürthle cell neoplasm.
RkJQdWJsaXNoZXIy MTk4NDMw